Home/Pipeline/KM-023

KM-023

Severe Keratoderma and Ichthyosis

PreclinicalActive

Key Facts

Indication

Severe Keratoderma and Ichthyosis

Phase

Preclinical

Status

Active

Company

About Kamari Pharma

TRPV3 inhibitor biotech focused on rare dermatologic disorders.

View full company profile

Therapeutic Areas

Dermatology Rare Diseases